Nutritional formulations including human milk oligosaccharides and antioxidants and uses thereof

Abstract

Disclosed are nutritional compositions including human milk oligosaccharides in combination with long chain polyunsaturated fatty acids and/or carotenoids that can be administered to preterm infants, term infants, toddlers, and children for reducing inflammation and the incidence of inflammatory diseases.

1 - 30 . (canceled) 
     
     
         31 . A synthetic pediatric formula comprising:
 hydrolyzed protein;   from about 0.01 mg/mL to about 10 mg/mL of at least one of 6′-sialyllactose, 3′-sialyllactose 2′-fucosyllactose, 3-fucosyllactose, lacto-N-tetraose, lacto-N-neotetraose, and lacto-N-fucopentaose;   vitamin A;   from about 0.025 mg/mL to about 0.130 mg/mL of docosahexaenoic acid;   from about 10 mg/L to about 200 mg/L of a monomeric monophosphate nucleotide component;   wherein the synthetic pediatric formula is shelf stable for at least 3 months.   
     
     
         32 . The synthetic pediatric formula of  claim 31  comprising 0.01 mg/mL to about 5 mg/mL of at least one of 2′-fucosyllactose, 3′-sialylactose, and 6′-sialyllactose. 
     
     
         33 . The synthetic pediatric formula of  claim 31 , wherein the human milk oligosaccharide component comprises 2′-fucosyllactose which is present in a concentration of from about 0.01 mg/mL to 5 mg/mL. 
     
     
         34 . The synthetic pediatric formula of  claim 31 , further comprising from about 0.001 µg/mL to about 5 µg/mLof at least one of lutein, lycopene, and beta-carotene. 
     
     
         35 . The synthetic pediatric formula of  claim 31 , wherein the monomeric monophosphate nucleotide component comprises cytidine 5′-monophosphate, adenosine 5′-monophosphate, guanosine 5′-monophosphate, and uridine 5′-monophosphate. 
     
     
         36 . The synthetic pediatric formula of  claim 31 , wherein at least one monomeric monophosphate nucleotide is a free acid and at least one other monomeric monophosphate nucleotide is a salt. 
     
     
         37 . The synthetic pediatric formula of  claim 31 , wherein the docosahexaenoic acid provides less than 1% by weight of the total fat in the synthetic pediatric formula. 
     
     
         38 . The synthetic pediatric formula of  claim 31 , further comprising high oleic safflower oil, soybean oil, and coconut oil. 
     
     
         39 . The synthetic pediatric formula of  claim 31 , further comprising lactose and fructooligosaccharide. 
     
     
         40 . The synthetic pediatric formula of  claim 31 , wherein the hydrolyzed protein is extensively hydrolyzed protein. 
     
     
         41 . A synthetic pediatric formula comprising:
 hydrolyzed protein;   from about 0.01 mg/mL to about 10 mg/mL of at least one of 2′-fucosyllactose, 3-fucosyllactose, 6′-sialyllactose, 3′-sialylactose, and lacto-N-tetraose;   vitamin A;   from about 0.025 mg/mL to about 0.130 mg/mL of docosahexaenoic acid; and   wherein the synthetic pediatric formula is shelf stable from about 3 months to about 24 months.   
     
     
         42 . The synthetic pediatric formula of  claim 41 , wherein 3′-sialyllactose and 6′-sialyllactose, when present, are present in a weight ratio of from about 1:2 to about 2:1. 
     
     
         43 . The synthetic pediatric formula of  claim 41 , wherein 2′-fucosyllactose is present in a concentration of from about 0.01 mg/mL to 5 mg/mL. 
     
     
         44 . The synthetic pediatric formula of  claim 41 , wherein the synthetic pediatric formula is substantially free of carotenoids other than lutein, lycopene, and beta-carotene. 
     
     
         45 . The synthetic pediatric formula of  claim 41 , wherein the monomeric monophosphate nucleotide component comprises cytidine 5′-monophosphate, adenosine 5′-monophosphate, guanosine 5′-monophosphate, and uridine 5′-monophosphate. 
     
     
         46 . The synthetic pediatric formula of  claim 41 , wherein the docosahexaenoic acid provides less than 1% by weight of the total fat in the synthetic pediatric formula. 
     
     
         47 . The synthetic pediatric formula of  claim 41 , wherein at least one monomeric monophosphate nucleotide is a free acid and at least one other monomeric monophosphate nucleotide is a salt. 
     
     
         48 . The synthetic pediatric formula of  claim 41 , comprising a combination of lutein, lycopene, and beta-carotene. 
     
     
         49 . The synthetic pediatric formula of  claim 41 , further comprising high oleic safflower oil, soybean oil, and coconut oil. 
     
     
         50 . A method of reducing inflammation in an infant, toddler, or child in need thereof, the method comprising administering to the infant, toddler, or child a synthetic pediatric formula comprising:
 hydrolyzed protein;   from about 0.01 mg/mL to about 10 mg/mL of at least one of 6′-sialyllactose, 3′-sialyllactose 2′-fucosyllactose, 3-fucosyllactose, lacto-N-tetraose, and lacto-N-neotetraose;   vitamin A;   from about 0.025 mg/mL to about 0.130 mg/mL of docosahexaenoic acid;   wherein the docosahexaenoic acid provides less than 1% by weight of the total fat in the synthetic pediatric formula;   wherein the synthetic pediatric formula is shelf stable for at least 3 months.